Illumina

Meet the MiSeq i100 Series – the new standard in sequencing simplicity with a 3-step setup, onboard DRAGEN analysis, and same-day results to accelerate genomic discovery and insights: https://bit.ly/4eTqugz

A potential germline flag on a CGP report offers an opportunity for patients to uncover vital hereditary risk information, but only if there is appropriate follow-up, referral and testing. We collaborated with Allegheny Health Network on a study examining referral patterns in a large community setting and its impact on patient care. If you missed the poster presentation at #AMPath24, read about the study here: https://bit.ly/4eNHZOM

Our new MiSeq i100 Series is changing the game for researchers worldwide. Hear what early access users are saying about our latest innovation: 🧬 “We can launch a run in the morning and have the result at the beginning of the afternoon...It's really a new paradigm for us.” — Yannick MARIE, Institut du Cerveau – Paris Brain Institute 🧬 “With this new system, we can generate high-quality data every single day. It’s probably the fastest sequencer available.” — Christopher Noune, Australian Genome Research Facility Ltd. (AGRF) 🧬 “I’ve been waiting for this for years...the reagents are always ready to use, so you can plan and start a run within the next 15 minutes.” — Geneviève DonPierre, Génome Québec Learn more about how the MiSeq i100 Series is transforming lab operations and opening up new possibilities: https://bit.ly/3Zm7a6w

As part of a multi-year study in partnership with Providence and Microsoft Research, collaborators have found that CGP has identified more genetic anomalies compared to smaller gene panels, enabling precision therapies and improved outcomes for patients with advanced cancers. For more on this study and its impact: https://bit.ly/4fEsw50 #AMPath24

What makes a tool truly innovative? Simplicity and power. Emmanuel Naouri recently shared how the MiSeq i100 Series achieves both—transforming the way labs approach next-generation sequencing. Curious how it works? Don’t miss the chance to see it in person at #AMPath24, and read the feature in The Scientist: https://bit.ly/3ZhxkY3

“Illumina’s innovation engine continues to evolve to fit the diverse needs of our customers, and the expansion of our TruSight Oncology portfolio addresses both research and clinical customer needs.” At #AMPath24, Illumina product leaders Heather Robinson, MS MBA and Samyuktha Dasari (she/her) discussed the opportunity to expand comprehensive genomic profiling through RUO and IVD solutions.

Join us at #AMPath24 to discuss the latest research and growing evidence for the clinical utility of CGP, as well as challenges in precision medicine implementation. On Thursday, we will unveil plans for our newest cancer research assay, TruSight Oncology 500 v2, in a spotlight presentation on the TruSight Oncology portfolio and its role in enabling adoption of CGP. Stop by our booth to learn more!

Innovation doesn’t happen overnight, it’s often the result of relentless customer focus by experts like Dorothea Agius and Joe Cottrell on the Systems Integration team. By starting with feedback from customers, the team was able to prioritize applications and test the MiSeq i100 Series with their most adventurous research ideas in mind. Learn how Joe, Dorothea, and team brought together the best elements of Illumina sequencing technology to create a powerful, user-friendly platform for researchers everywhere: https://bit.ly/4hRrT9E

Eric Kelsic and his team are driven by one thing: Accelerating drug discovery. Hear how Dyno Therapeutics is finding ways to keep people healthier, longer with the help of Illumina technology.

“These results further illustrate the paradigm shift in clinical practice in oncology. Patients are seeing better outcomes from precision treatments based on a tumor’s molecular profile compared to conventional approaches used to treat cancer.” – Swaroop Aradhya, VP of Medical and Clinical Affairs at Illumina. Powerful study of CGP, in partnership with Providence and Microsoft Research, published today in the Journal of Clinical Oncology. Congratulations to John Fox, Bela Bapat, Pratheesh Sathyan PhD and the many team members who contributed to this important work over several years.